Julia D Interrante1, Stacey L P Scroggs2, Carol J Hogue3, Jan M Friedman4, Jennita Reefhuis5, Michael W Jann6, Cheryl S Broussard7. 1. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Preven-tion, Atlanta, Georgia; Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee. 2. New Mexico State University, Las Cruces, New Mexico. 3. Rollins School of Public Health, Emory University, Atlanta, Georgia. 4. Department of Medical Genetics and Genomics, University of British Columbia, Vancouver, British Columbia, Canada. 5. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia. 6. University of North Texas Health Science Center, Fort Worth, Texas. 7. National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Preven-tion, Atlanta, Georgia. ORCID: https://orcid.org/0000-0001-6428-8523.
Abstract
OBJECTIVE: Examine the relationship between prescription opioid analgesic use during pregnancy and preterm birth or term low birthweight. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from the National Birth Defects Prevention Study, a US multisite, population-based study, for births from 1997 to 2011. We defined exposure as self-reported prescription opioid use between one month before conception and the end of pregnancy, and we dichotomized opioid use duration by ≤7 days and >7 days. MAIN OUTCOME MEASURES: We examined the association between opioid use and preterm birth (defined as gestational age <37 weeks) and term low birthweight (defined as <2500 g at gestational age ≥37 weeks). RESULTS: Among 10,491 singleton mother/infant pairs, 470 (4.5 percent) reported opioid use. Among women reporting opioid use, 236 (50 percent) used opioids for > 7 days; codeine (170, 36 percent) and hydrocodone (163, 35 percent) were the most commonly reported opioids. Opioid use was associated with slightly increased risk for preterm birth [adjusted odds ratio, 1.4; 95 percent confidence interval, 1.0, 1.9], particularly with hydrocodone [1.6; 1.0, 2.6], meperidine [2.5; 1.2, 5.2], or morphine [3.0; 1.5, 6.1] use for any duration; however, opioid use was not significantly associated with term low birthweight. CONCLUSIONS: Preterm birth occurred more frequently among infants of women reporting prescription opioid use during pregnancy. However, we could not determine if these risks relate to the drug or to indications for use. Patients who use opioids during pregnancy should be counseled by their practitioners about this and other potential risks associated with opioid use in pregnancy.
OBJECTIVE: Examine the relationship between prescription opioid analgesic use during pregnancy and preterm birth or term low birthweight. DESIGN, SETTING, AND PARTICIPANTS: We analyzed data from the National Birth Defects Prevention Study, a US multisite, population-based study, for births from 1997 to 2011. We defined exposure as self-reported prescription opioid use between one month before conception and the end of pregnancy, and we dichotomized opioid use duration by ≤7 days and >7 days. MAIN OUTCOME MEASURES: We examined the association between opioid use and preterm birth (defined as gestational age <37 weeks) and term low birthweight (defined as <2500 g at gestational age ≥37 weeks). RESULTS: Among 10,491 singleton mother/infant pairs, 470 (4.5 percent) reported opioid use. Among women reporting opioid use, 236 (50 percent) used opioids for > 7 days; codeine (170, 36 percent) and hydrocodone (163, 35 percent) were the most commonly reported opioids. Opioid use was associated with slightly increased risk for preterm birth [adjusted odds ratio, 1.4; 95 percent confidence interval, 1.0, 1.9], particularly with hydrocodone [1.6; 1.0, 2.6], meperidine [2.5; 1.2, 5.2], or morphine [3.0; 1.5, 6.1] use for any duration; however, opioid use was not significantly associated with term low birthweight. CONCLUSIONS: Preterm birth occurred more frequently among infants of women reporting prescription opioid use during pregnancy. However, we could not determine if these risks relate to the drug or to indications for use. Patients who use opioids during pregnancy should be counseled by their practitioners about this and other potential risks associated with opioid use in pregnancy.
Authors: P W Yoon; S A Rasmussen; M C Lynberg; C A Moore; M Anderka; S L Carmichael; P Costa; C Druschel; C A Hobbs; P A Romitti; P H Langlois; L D Edmonds Journal: Public Health Rep Date: 2001 Impact factor: 2.792
Authors: Brian T Bateman; Sonia Hernandez-Diaz; James P Rathmell; John D Seeger; Michael Doherty; Michael A Fischer; Krista F Huybrechts Journal: Anesthesiology Date: 2014-05 Impact factor: 7.892
Authors: Julia D Interrante; Elizabeth C Ailes; Jennifer N Lind; Marlene Anderka; Marcia L Feldkamp; Martha M Werler; Lockwood G Taylor; James Trinidad; Suzanne M Gilboa; Cheryl S Broussard Journal: Ann Epidemiol Date: 2017-09-20 Impact factor: 3.797
Authors: Rishi J Desai; Krista F Huybrechts; Sonia Hernandez-Diaz; Helen Mogun; Elisabetta Patorno; Karol Kaltenbach; Leslie S Kerzner; Brian T Bateman Journal: BMJ Date: 2015-05-14
Authors: Ayesha C Sujan; Patrick D Quinn; Martin E Rickert; Kelsey K Wiggs; Paul Lichtenstein; Henrik Larsson; Catarina Almqvist; A Sara Öberg; Brian M D'Onofrio Journal: PLoS Med Date: 2019-12-02 Impact factor: 11.069